Upadacitinib as Rescue Therapy in a Pregnant Patient With IBD

Area of Science:

• Pharmacology
• Gastroenterology
• Reproductive Medicine

Background:

• Upadacitinib is an oral Janus kinase (JAK) inhibitor approved for moderate-to-severe ulcerative colitis (UC).
• Its efficacy is established, but safety data, particularly during pregnancy, are limited outside animal studies and case reports.
• Inflammatory bowel disease (IBD) often affects women of childbearing age, necessitating treatment options during pregnancy.

Observation:

• This case report details a patient with left-sided UC experiencing recurrent disease flares with pregnancies.
• The patient successfully responded to upadacitinib treatment during her fourth pregnancy.
• This observation highlights a potential therapeutic option for UC during gestation.

Findings:

• Upadacitinib demonstrated effectiveness in managing UC exacerbations during pregnancy in this patient.
• The treatment was tolerated, suggesting potential safety in this context, though further investigation is crucial.
• This case adds to the limited real-world data on JAK inhibitor use in pregnant IBD patients.

Implications:

• This case suggests upadacitinib may be a viable treatment option for pregnant patients with UC.
• Further clinical studies are essential to establish the safety and efficacy profile of JAK inhibitors in pregnancy.
• These findings may inform clinical decision-making for managing IBD in pregnant individuals.